Pharmaceutical Business review

Teva establishes Global Specialty Medicines group

The company has named Dr. Rob Koremans as the president and CEO of Global Specialty Medicines.

Koremans will report to Teva Pharmaceutical Industries president and CEO Dr. Jeremy Levin and will continue to serve on Teva’s executive committee.

Koremans held key roles at several companies such as Sanofi SA, Serono Group, Grunenthal, Sanofi group.

Teva develops, produces and markets affordable generic drugs in addition to specialty pharmaceuticals and active pharmaceutical ingredients.